Skip to main content

Table 2 Response, PFS, OS and toxicity rate

From: FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer

Response to treatment n % p
 Complete response 3 4.7  
 Partial response 50 78.1  
 Stable disease 5 7.8  
 Progressive disease 6 9.4  
Wild-type KRAS and NRAS PFS Months or % %95 CI (min-max)  
 Median follow-up 18.9 2.0–51.0  
 Median PFS 13 9.6–16.4  
 6-months PFS 77.3   
 1-year PFS 50.1   
 2-year PFS 16.9   
 3-year PFS 3.4   
Wild-type KRAS and NRAS OS
 Median OS 26 23.1–29.2  
 6-months OS 90.4   
 1-year OS 79.5   
 2-year OS 53.7   
 3-year OS 31.1   
Tumour location
 Right colon PFS 4 1.5–6.5 0.02
 Left colon PFS 14 10.8–17.2  
 Right colon OS 18 5.3–30.7 0.02
 Left colon OS 26 23.1–28.9  
Metastasectomy
 Yes PFS 17 14.3–19.7 0.02
 No PFS 8 5.6–10.4  
 Yes OS 40 19.9–60.1 0.007
 No OS 22 17.7–26.4  
Metastases diagnosed
 Synchronous PFS 12 7.0–17.0 0.28
 Metachronous PFS 17 3.6–30.4  
 Synchronous OS 23 16.9–29.1 0.21
 Metachronous OS 26 21.7–30.3  
Toxicity Grade (all) Grade (1–2) Grade (3–4)
 Acne-like rash %60.9 %54.6 %6.3
 Diarrhoea %36.2 %31.5 %4.7
 Neutropenia %34.7 %25.5 %9.2
  1. PFS progression-free survival, OS overall survival